Anti-tumour necrosis factor therapy in seronegative spondyloarthritis.

S19–23. 13 Desai SR, Veeraraghavan S, Hansell DM, Nikolakopolou A et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004;232:560–7. 14 Wells AU, Hansell DM, Haslam PL, Rubens MB et al. Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis. Am J Respir Crit Care Med 1998;157(5 Pt 1):1474–82. 15 White B. Interstitial lung disease in scleroderma. Review. Rheum Dis Clin North Am 2003;29:371–90. 16 Mukerjee D, St George D, Coleiro B, Knight C et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62: 1088–93. 17 Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Review. Rheum Dis Clin North Am 2003;29:335–49, vii. 18 Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Review. Ann Rheum Dis 2004;63:1009–14. 19 Mathou NG, Lovat LB, Thorpe SM, Bown SG. Nd:YAG laser induces long-term remission in transfusion-dependent patients with watermelon stomach. Lasers Med Sci 2004;18:213–18.